New Alzheimer’s treatment linked to slower cognitive decline

A new treatment for Alzheimer’s disease is showing promising early results in early clinical trials.

Published in a study in Nature Medicine, researchers from Western University, Stanford University and the University of California, San Francisco, evaluated the effectiveness of a drug tentatively called LM11A-31, which targets a specific neurotrophin receptor.

According to the study, there were “significant differences between drugs and placebo” and the drug slowed the progression of cognitive decline after a study of 242 participants, all of whom ranged from mild to moderate Alzheimer’s disease.

The targeted neurotrophin receptor, called p75, promotes cell survival and synaptic plasticity through multiple pathways and may act as “a powerful and fundamental molecular signaling switch for neuronal survival and synaptic integrity,” the researchers said.

Study participants were selected between 2017 and 2020, with 211 completing the study during a 26-week visit. Participants received a placebo, 200 mg, or 400 mg dose of the drug.

In some cases, the drug LM11A-31 caused a 50% delay in cognitive decline compared to the placebo.

“The exploratory findings encourage larger studies with longer treatment durations to address the hypothesis that modulation of p75NTR with small molecules could be a disease-modifying therapy in Alzheimer’s disease,” the researchers wrote.

Back To Top